Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
نویسندگان
چکیده
Functional gut disorders, including diarrhea-predominant irritable bowel syndrome, are highly prevalent conditions worldwide that significantly impact health economy and patient quality of life, yet lacking fully satisfactory therapeutic options. These circumstances fostered research on various molecules with more specific therapeutic targets, including opioid receptors. Eluxadoline (Allergan's Vibercy® in the USA, Truberzi® in Europe) is a locally-acting mixed mu- and kappa-opioid receptor agonist, and delta-opioid receptor antagonist, that was licensed in 2015 by the Food and Drug Administration (FDA) and in 2016 by the European Medicines Agency (EMA) for use in diarrhea-predominant irritable bowel syndrome. Eluxadoline provides, with advantage over the current standard of care, control of both stool consistency and abdominal pain, good tolerability in most cases, and improved quality of life, hence it deserves consideration when approaching a patient with this disorder. As with any recently approved therapy, adequate pharmacovigilance is to be expected, as well as studies to inform on different scenarios such as on-demand therapy, loss of response assessment, use as rescue therapy for other molecules, and cost-effectiveness, to further characterize and more accurately position eluxadoline within the therapeutic spectrum.
منابع مشابه
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline's efficacy in reducing symptoms related to IBS-D. Clinical trial results and postmarketing reports show a risk of pancreatitis in patients...
متن کاملPrevalence of Celiac Disease in Patients with Irritable Bowel Syndrome in Kerman, Iran
Background & Aims: Celiac disease or gluten-sensitive enteropathy is a relatively uncommon digestive disease. Moreover, irritable bowel syndrome (IBS) is a common functional bowel disorder. Some IBS patients have celiac disease, with similar IBS symptoms in addition to some serious complications. The only possible treatment for this condition is changing the patients diet (gluten free diet). Gi...
متن کاملMolecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers
Eluxadoline, an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist developed for the treatment of diarrhea-predominant irritable bowel syndrome, normalizes gastrointestinal (GI) transit and defecation under conditions of novel environment stress or post-inflammatory altered GI function. Furthermore, compared to loperamide, which is used to treat non-specific ...
متن کاملبررسی شیوع سندرم روده تحریک‌پذیر: مطالعه‌ای مبتنی بر جمعیت
Abstract Background & Aims : Irritable bowel syndrome is a common functional gastro-intestinal disease. Patients can experience symptoms for many years. These symptoms have significant impact on patient’s quality of life. There is a little information about irritable bowel syndrome in Iran. The aim of the present study was to determine the prevalence of irritable bowel syndrome by using the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
دوره 109 11 شماره
صفحات -
تاریخ انتشار 2017